Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Security

BSEM · BioStem Technologies, Inc.

BSEMNASDAQCommon stockCurrentCIK 1658678Updated Sep 26, 2026

Company: BioStem Technologies, Inc. →

Name history
BIOSTEM TECHNOLOGIES · through Oct 28, 2025

BSEM price & chart

Provider market data

Loading TradingView…

NASDAQ:BSEM on TradingView ↗

TradingView · Data may be delayed

In the news

Seeking Alpha

Recent filings

  1. D filing

    D · 2026-09-21 · 0001213900-26-101819

  2. S-1 filing

    S-1 · 2026-09-18 · 0001213900-26-101505

  3. Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD Disclosure

    Items 1.01, 3.02, 7.01, 9.01

    8-K · 2026-09-18 · 0001193125-26-395556

  4. 4 filing

    4 · 2026-09-17 · 0001193125-26-394391

  5. 4 filing

    4 · 2026-09-17 · 0001193125-26-394398

Show 5 more recent filings

  1. 4 filing

    4 · 2026-09-17 · 0001193125-26-394390

  2. 4 filing

    4 · 2026-09-17 · 0001193125-26-394388

  3. 4 filing

    4 · 2026-08-28 · 0002147392-26-000005

  4. 4 filing

    4 · 2026-08-28 · 0002146882-26-000004

  5. 4 filing

    4 · 2026-08-28 · 0001441461-26-000005

Offerings

Registration 333-299025

S-1 · 2026-09-18 · 0001213900-26-101505

Terms from the governing filing for this registration; not a claim that the offering is open today.

Registration 333-297780

S-1/A · 2026-08-07 · 0001213900-26-086804

Terms from the governing filing for this registration; not a claim that the offering is open today.

Filing attachments

bsem-ex99_1.htm · 8-K · 2026-09-18

EX-99.1 4 bsem-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility POMPANO BEACH, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced it has entered into a $40 million Committed Equity Facility (the “CEF”)…

8-K · 2026-09-18 · 0001193125-26-395556

Read attachment ↗
bsem-ex99_1.htm · 8-K · 2026-08-12

EX-99.1 2 bsem-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 BioStem Technologies Reports Second Quarter 2026 Financial Results Generates 29% sequential revenue growth, increasing to $7.9 million; Raises full-year 2026 revenue guidance Uplists to Nasdaq Capital Market POMPANO BEACH, FL, August 12, 2026 (GLOBE NEWSWIRE) - BioStem Technologies, Inc. (Nasdaq: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allog…

8-K · 2026-08-12 · 0001193125-26-347211

Read attachment ↗
bsem-ex99_1.htm · 8-K · 2026-08-07

EX-99.1 2 bsem-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 BioStem Technologies Announces Nasdaq Uplisting Trading to Commence on August 7, 2026 POMPANO BEACH, Fla., August 6, 2026 - BioStem Technologies Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that The Nasdaq Stock Market LLC (“Nasdaq”) has completed its review of the Company’…

8-K · 2026-08-07 · 0001193125-26-340271

Read attachment ↗